Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants With Schizophrenia

NCT06315283 is registered in ClinicalTrials.gov with Teva Branded Pharmaceutical Products R&D LLC as lead sponsor.

NCT NCT06315283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06315283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants With Schizophrenia
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Phase
Phase 1
Overall status
Completed
Start date
March 20, 2024
Completion date
September 4, 2025
Enrollment
153 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia